SG Americas Securities LLC Acquires 1,140 Shares of Tourmaline Bio, Inc. (NASDAQ:TRML)

SG Americas Securities LLC raised its holdings in Tourmaline Bio, Inc. (NASDAQ:TRML) by 3.4% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 34,812 shares of the company’s stock after buying an additional 1,140 shares during the quarter. SG Americas Securities LLC owned about 0.14% of Tourmaline Bio worth $706,000 at the end of the most recent quarter.

Other large investors have also recently made changes to their positions in the company. Geode Capital Management LLC grew its position in shares of Tourmaline Bio by 6.4% in the 3rd quarter. Geode Capital Management LLC now owns 482,078 shares of the company’s stock worth $12,396,000 after buying an additional 29,005 shares during the last quarter. Wellington Management Group LLP boosted its position in shares of Tourmaline Bio by 72.8% during the third quarter. Wellington Management Group LLP now owns 65,741 shares of the company’s stock valued at $1,690,000 after purchasing an additional 27,707 shares in the last quarter. State Street Corp boosted its position in shares of Tourmaline Bio by 25.6% during the third quarter. State Street Corp now owns 411,980 shares of the company’s stock valued at $10,592,000 after purchasing an additional 83,949 shares in the last quarter. Charles Schwab Investment Management Inc. boosted its position in shares of Tourmaline Bio by 3.5% during the third quarter. Charles Schwab Investment Management Inc. now owns 63,571 shares of the company’s stock valued at $1,634,000 after purchasing an additional 2,147 shares in the last quarter. Finally, Barclays PLC boosted its position in shares of Tourmaline Bio by 283.7% during the third quarter. Barclays PLC now owns 31,833 shares of the company’s stock valued at $819,000 after purchasing an additional 23,536 shares in the last quarter. 91.89% of the stock is currently owned by institutional investors.

Tourmaline Bio Price Performance

Tourmaline Bio stock opened at $16.33 on Thursday. The stock has a market capitalization of $418.70 million, a price-to-earnings ratio of -5.79 and a beta of 2.36. Tourmaline Bio, Inc. has a 1-year low of $12.12 and a 1-year high of $48.31. The business has a fifty day moving average price of $21.22 and a 200-day moving average price of $21.10.

Tourmaline Bio (NASDAQ:TRML) last issued its earnings results on Thursday, November 7th. The company reported ($0.78) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.84) by $0.06. On average, equities research analysts anticipate that Tourmaline Bio, Inc. will post -2.99 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

TRML has been the subject of a number of recent research reports. Cantor Fitzgerald reiterated an “overweight” rating and set a $25.00 price objective on shares of Tourmaline Bio in a research note on Wednesday, December 11th. BMO Capital Markets started coverage on Tourmaline Bio in a research report on Friday, December 6th. They set an “outperform” rating and a $50.00 price objective for the company. HC Wainwright reiterated a “buy” rating and set a $49.00 price objective on shares of Tourmaline Bio in a research report on Wednesday, December 11th. Finally, Guggenheim reissued a “buy” rating on shares of Tourmaline Bio in a report on Wednesday, December 11th. Six equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat, Tourmaline Bio presently has a consensus rating of “Buy” and an average target price of $54.00.

Tourmaline Bio Profile

Tourmaline Bio, Inc operates as a clinical biotechnology company that develops medicines for patients with life-altering immune and inflammatory diseases. It develops TOUR006, a human anti-IL-6 monoclonal antibody that selectively binds to interleukin-6, a key proinflammatory cytokine involved in the pathogenesis of many autoimmune and inflammatory disorders.